

Haemonetics Corporation Financial Summary
(Unaudited data in thousands, except per share data)

Consolidated Statements of Income for the Third Quarter FY09

	12/27/08 As Reported	12/29/07 As Reported	% Inc/(Dec) vs Prior Year
NET REVENUES	<u>\$155,447</u>	<u>\$134,587</u>	15.5%
Gross profit	78,296	66,558	17.6%
R&D	5,840	5,529	5.6%
S,G&A	47,965	41,432	15.8%
Operating expenses	<u>53,805</u>	<u>46,961</u>	14.6%
Operating income	24,491	19,597	25.0%
Interest income, net	449	1,070	(58.0%)
Other (expense)/income, net	<u>(1,451)</u>	<u>225</u>	(744.9%)
Income before taxes	23,489	20,892	12.4%
Tax expense	7,273	6,538	11.2%
NET INCOME	<u><u>\$16,216</u></u>	<u><u>\$14,354</u></u>	13.0%
Net income per common share assuming dilution	\$0.62	\$0.54	14.5%
Weighted average number of shares			
Basic	25,375	25,500	
Diluted	26,056	26,437	
Profit Margins:			Inc/(Dec) vs prior year profit margin %
Gross profit	50.4%	49.5%	<u>0.9%</u>
R&D	3.8%	4.1%	(0.3%)
S,G&A	30.9%	30.8%	0.1%
Operating income	15.8%	14.6%	1.2%
Income before taxes	15.1%	15.5%	(0.4%)
Net income	10.4%	10.7%	(0.3%)

Consolidated Statements of Income for FY09 Year-To-Date

	12/27/08 As Reported	12/29/07 As Reported	% Inc/(Dec) vs Prior Year
NET REVENUES	\$445,482	\$377,701	17.9%
Gross profit	226,022	187,940	20.3%
R&D	16,901	18,532	(8.8%)
S,G&A	141,687	119,418	18.6%
Operating expenses	158,588	137,950	15.0%
Operating income	67,434	49,990	34.9%
Interest income, net	1,569	4,037	(61.1%)
Other (expense)/income, net	(2,366)	1,905	(224.2%)
Income before taxes	66,637	55,932	19.1%
Tax expense	21,272	17,733	20.0%
NET INCOME	\$45,365	\$38,199	18.8%
Net income per common share assuming dilution	\$1.73	\$1.43	21.5%
Weighted average number of shares			
Basic	25,340	25,881	
Diluted	26,163	26,776	
Profit Margins:			Inc/(Dec) vs prior year profit margin %
Gross profit	50.7%	49.8%	0.9%
R&D	3.8%	4.9%	(1.1%)
S,G&A	31.8%	31.6%	0.2%
Operating income	15.1%	13.2%	1.9%
Income before taxes	15.0%	14.8%	0.2%
Net income	10.2%	10.1%	0.1%

Revenue Analysis for the Third Quarter and Year-To-Date FY09

	Third Quarter		
	12/27/08 As Reported	12/29/07 As Reported	% Increase vs. Prior Year
Revenues by Geography			
United States	\$73,448	\$61,481	19.5%
International	\$81,999	\$73,106	12.2%
Net Revenues	<u>\$155,447</u>	<u>\$134,587</u>	15.5%
Disposable Revenues by Product Family			
Donor:			
Plasma	\$53,594	\$41,253	29.9%
Blood Bank	\$36,435	\$33,207	9.7%
Red Cell	\$13,051	\$12,478	4.6%
	<u>\$103,080</u>	<u>\$86,938</u>	18.6%
Patient:			
Surgical / Diagnostic	\$22,967	\$18,981	21.0%
OrthoPAT	\$9,112	\$9,086	0.3%
	<u>\$32,079</u>	<u>\$28,067</u>	14.3%
Subtotal	\$135,159	\$115,005	17.5%
Equipment	\$10,246	\$8,485	20.8%
Software & Services	\$10,042	\$11,097	(9.5%)
Net Revenues	<u>\$155,447</u>	<u>\$134,587</u>	15.5%
Nine Months Ended			
	12/27/08 As Reported	12/29/07 As Reported	% Increase vs. Prior Year
Revenues by Geography			
United States	\$205,748	\$170,085	21.0%
International	\$239,734	\$207,616	15.5%
Net Revenues	<u>\$445,482</u>	<u>\$377,701</u>	17.9%
Disposable Revenues by Product Family			
Donor:			
Plasma	\$150,386	\$114,788	31.0%
Blood Bank	\$108,388	\$100,399	8.0%
Red Cell	\$36,651	\$34,257	7.0%
	<u>\$295,425</u>	<u>\$249,444</u>	18.4%
Patient:			
Surgical / Diagnostic	\$66,077	\$50,907	29.8%
OrthoPAT	\$26,301	\$25,122	4.7%
	<u>\$92,378</u>	<u>\$76,029</u>	21.5%
Subtotal	\$387,803	\$325,473	19.2%
Equipment	\$27,388	\$22,286	22.9%
Software & Services	\$30,291	\$29,942	1.2%
Net Revenues	<u>\$445,482</u>	<u>\$377,701</u>	17.9%

Consolidated Balance Sheets

	Period ending	
	12/27/08	3/29/08
<u>Assets</u>		
Cash & cash equivalents	\$125,325	\$133,553
Accounts receivable, net	124,575	120,252
Inventories, net	73,557	65,388
Other current assets	30,435	40,241
Total current assets	353,892	359,434
Net PP&E	129,470	116,484
Other assets	138,986	133,032
 Total assets	 \$622,348	 \$608,950

	Period ending	
	9/27/08	3/29/08
<u>Liabilities & Stockholders' Equity</u>		
S/T debt & current maturities	\$4,434	\$6,326
Other current liabilities	81,100	91,351
Total current liabilities	85,534	97,677
Long-term debt	5,522	6,037
Other long-term liabilities	15,504	11,048
Stockholders' equity	515,788	494,188
 Total liabilities & equity	 \$622,348	 \$608,950

FREE CASH FLOW RECONCILIATION

	<u>Three Months Ended</u>	
	<u>12/27/08</u>	<u>12/29/07</u>
GAAP CASH FLOW FROM OPERATIONS	<u>\$30,881</u>	<u>\$24,876</u>
Capital expenditures	(16,895)	(15,242)
Proceeds from sale of property, plant and equipment	<u>25</u>	<u>1,187</u>
Net investment in property, plant and equipment	<u>(16,870)</u>	<u>(14,055)</u>
Free Cash Flow	<u><u>\$14,011</u></u>	<u><u>\$10,821</u></u>
	<u>Nine Months Ended</u>	
	<u>12/27/08</u>	<u>12/29/07</u>
GAAP CASH FLOW FROM OPERATIONS	<u>\$72,658</u>	<u>\$45,754</u>
Capital expenditures	(45,670)	(42,497)
Proceeds from sale of property, plant and equipment	<u>2,522</u>	<u>3,149</u>
Net investment in property, plant and equipment	<u>(43,148)</u>	<u>(39,348)</u>
Free Cash Flow	<u><u>\$29,510</u></u>	<u><u>\$6,406</u></u>

Haemonetics Corporation Financial Summary Reconciliation of Non-GAAP Measures

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a significant transformation of our business during the third quarter and first nine months of our fiscal years 2009 and 2008. This transformation resulted in the formation of a shared service center in Europe, exiting various offices across Europe and Japan and, most recently, in repositioning our technical operations organization. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

Non-GAAP Gross Profit

The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP S,G&A and Non-GAAP Operating Expenses

The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development. We establish our budgets, forecasts, and performance targets excluding these costs.

Non-GAAP Operating Income and Non-GAAP Income before Income Taxes

The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP Net Income and Earnings per Share

The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.

Reconciliation of Non-GAAP Measures for the Third Quarter of FY09 and FY08

	12/27/08	12/29/07
GAAP Gross Profit	\$78,296	\$66,558
Restructuring Costs	0	0
Non-GAAP Gross Profit	\$78,296	\$66,558
GAAP S,G&A	\$47,965	\$41,432
Restructuring Costs	(432)	(1,225)
Non-GAAP S,G&A	\$47,533	\$40,207
GAAP Operating Expenses	\$53,805	\$46,961
Restructuring Costs	(432)	(1,225)
Non-GAAP Operating Expenses	\$53,373	\$45,736
GAAP Operating Income	\$24,491	\$19,597
Restructuring Costs	432	1,225
Non-GAAP Operating income	\$24,923	\$20,822
GAAP Income before taxes	\$23,489	\$20,892
Restructuring Costs	432	1,225
Non-GAAP Income before taxes	\$23,921	\$22,117
GAAP Net Income	\$16,216	\$14,354
Restructuring Costs	432	1,225
Tax benefit associated with Restructuring Costs	(152)	(386)
Non-GAAP Net Income	\$16,496	\$15,193
GAAP Net Income per common share assuming dilution	\$0.62	\$0.54
Restructuring Costs after tax per common share assuming dilution	\$0.01	\$0.03
Non-GAAP Net Income per common share assuming dilution	\$0.63	\$0.57

Reconciliation of Non-GAAP Measures for the First Nine Months of FY09 and FY08

	12/27/08	12/29/07
GAAP Gross Profit	\$226,022	\$187,940
Restructuring Costs	72	0
Non-GAAP Gross Profit	\$226,094	\$187,940
GAAP S,G&A	\$141,687	\$119,418
Restructuring Costs	(2,605)	(4,009)
Non-GAAP S,G&A	\$139,082	\$115,409
GAAP Operating Expenses	\$158,588	\$137,950
Restructuring Costs	(2,605)	(4,009)
Non-GAAP Operating Expenses	\$155,983	\$133,941
GAAP Operating Income	\$67,434	\$49,990
Restructuring Costs	2,677	4,009
Non-GAAP Operating income	\$70,111	\$53,999
GAAP Income before taxes	\$66,637	\$55,932
Restructuring Costs	2,677	4,009
Non-GAAP Income before taxes	\$69,314	\$59,941
GAAP Net Income	\$45,365	\$38,199
Restructuring Costs	2,677	4,009
Tax benefit associated with Restructuring Costs	(939)	(1,341)
Non-GAAP NET INCOME	\$47,103	\$40,867
GAAP Net Income per common share assuming dilution	\$1.73	\$1.43
Restructuring Costs after tax per common share assuming dilution	\$0.07	\$0.10
Non-GAAP Net Income per common share assuming dilution	\$1.80	\$1.53